<div class="headers"><div>Figure 1.B, Hazard ratios for serious infections (Cox proportional hazards model) in tofacitinib-treated patients in the pooled phase II, phase III, and long-term extension study population. Values are the mean (95% confidence interval [95% CI]). DMARD  disease-modifying antirheumatic drug.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 1.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">B, Hazard ratios for serious infections (Cox proportional hazards model) in tofacitinib-treated patients in the pooled phase II, phase III, and long-term extension study population. Values are the mean (95% confidence interval [95% CI]). DMARD  disease-modifying antirheumatic drug.</p></td>
</tr>
</tbody>
</table>
